Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
Pascual
J
J
Servicio de Nefrología, Hospital Ramón y Cajal, Universidad de Alcalá, Carretera de Colmenar km 9, 100, E-28034 Madrid, Spain.
Marcén
R
R
Ortuño
J
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077552:Basiliximab; D002986:Clinical Trials as Topic; D000077561:Daclizumab; D004305:Dose-Response Relationship, Drug; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016030:Kidney Transplantation; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D011993:Recombinant Fusion Proteins
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000077561:Daclizumab